Panelists discussed whether there is any flexibility woven into the process of developing a clinical pathway, especially if a patient does not respond to a particular therapy or if a clinician wants to include a new therapy that may be better fit.
The panelists discussed whether there is any flexibility woven into the process of developing a clinical pathway, especially if a patient does not respond to a particular therapy or if a clinician wants to include a new therapy that may be better fit.
Kathy Lokay replied that flexibility is allowed for in a couple of different ways. From the beginning, committees consider which presentations are common enough to build them into pathway branches. Another thing to remember is that the overall goal of a pathway is not 100% adherence; pathways want to address 80% of patients with a disease. Additionally, physicians can go off a pathway at any time so long as they document a brief statement explaining their divergence and what they will be doing instead.
When new therapies are offered, Lokay said, they are immediately placed in a library for physicians to use if they do decide to off the pathway. If it is a significantly new therapy with the potential to change clinical practices then there may be an ad-hoc committee in order to address it as soon as possible. Otherwise, it will be addressed at the next quarterly meeting.
Lokay concluded that “ultimately everything comes back to that shared decision-making between the physician and the patient. The pathway should never drive an inappropriate decision.”
Michael Fisch, MD, agreed with Lokay on the point of flexibility within pathways saying that there still must be some nimbleness in the process in order to respond to evolving evidence, and to decide the best course of action for each individual person. It cannot be like the CDC guidelines for prescribing opioid use because they need the ability to make adjustments in real time.
“Really, these pathways to me are a way to summarize clinical and weigh in costs on a nimble basis as essentially a way of operationalizing a value framework,” finished Dr. Fisch.
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More